Until recently, there has been limited evidence linking psoriatic arthritis (PsA) and cardiovascular disease (CVD). However, a meta-analysis published April 25, 2016 reported patients with PsA have a 43% higher risk of having or developing CVD compared to individuals without psoriasis (1). The risk of individual cardiovascular outcomes was also increased, including myocardial infarction (68%), cerebrovascular diseases (22%) and heart failure (31%).
The meta-analysis included 32,973 patients with PsA from 11 observational studies. Only studies that examined CV outcomes and used a control population of individuals without psoriasis or rheumatic diseases were included – two factors that increase our confidence in this study’s results. However, study limitations, such as the inclusion of both cross-sectional and cohort studies, as well as differences in clinical settings, definitions of PsA, and adjustment of cofounders, could make the results of this meta-analysis less reliable.
Overall, these results suggest that patients with PsA should be considered at greater risk for CVD, and therefore primary risk prevention for CVD should be part of the standard of care for these patients.
- Polachek et al. Arthritis Care Res. 2016. DOI 10.1002/acr.22926